Meloxicam fast acting is under clinical development by Viatris and currently in Phase III for Post-Operative Pain. According to GlobalData, Phase III drugs for Post-Operative Pain have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Meloxicam fast acting’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Meloxicam fast acting overview

Meloxicam fast acting is under development for the treatment of opioid sparing treatment in post-surgery pain. The drug candidate acts by targeting cyclooxygenase 1 (COX1) and cyclooxygenase 2 (COX2) enzymes. 

Viatris overview

Viatris is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti- retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries. Viatris is headquartered in Canonsburg, Pennsylvania, the US.

For a complete picture of Meloxicam fast acting’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.